- Home
- NMG vs KMDA Comparison
NMG vs KMDA Comparison
Compare NMG & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- KMDA
- Stock Information
- Founded
- NMG 2011
- KMDA 1990
- Country
- NMG Canada
- KMDA Israel
- Employees
- NMG N/A
- KMDA N/A
- Industry
- NMG Other Metals and Minerals
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- NMG Basic Materials
- KMDA Health Care
- Exchange
- NMG Nasdaq
- KMDA Nasdaq
- Market Cap
- NMG 448.1M
- KMDA 398.5M
- IPO Year
- NMG 2017
- KMDA N/A
- Fundamental
- Price
- NMG $2.45
- KMDA $6.67
- Analyst Decision
- NMG Strong Buy
- KMDA Strong Buy
- Analyst Count
- NMG 3
- KMDA 2
- Target Price
- NMG $4.22
- KMDA $13.00
- AVG Volume (30 Days)
- NMG 1.9M
- KMDA 78.8K
- Earning Date
- NMG 11-14-2025
- KMDA 11-10-2025
- Dividend Yield
- NMG N/A
- KMDA 3.00%
- EPS Growth
- NMG N/A
- KMDA 27.97
- EPS
- NMG N/A
- KMDA 0.32
- Revenue
- NMG N/A
- KMDA $169,517,000.00
- Revenue This Year
- NMG N/A
- KMDA $14.49
- Revenue Next Year
- NMG N/A
- KMDA $10.12
- P/E Ratio
- NMG N/A
- KMDA $20.69
- Revenue Growth
- NMG N/A
- KMDA 9.67
- 52 Week Low
- NMG $1.22
- KMDA $5.54
- 52 Week High
- NMG $6.06
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- NMG 41.82
- KMDA 42.81
- Support Level
- NMG $2.75
- KMDA $6.82
- Resistance Level
- NMG $3.60
- KMDA $6.99
- Average True Range (ATR)
- NMG 0.42
- KMDA 0.19
- MACD
- NMG -0.12
- KMDA -0.00
- Stochastic Oscillator
- NMG 8.36
- KMDA 12.07
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.